MIRM * Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mirum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$788.18 |
| 52 Week High | US$788.18 |
| 52 Week Low | US$448.50 |
| Beta | 1.16 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 170.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| MIRM * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how MIRM * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how MIRM * performed against the MX Market.
Price Volatility
| MIRM * volatility | |
|---|---|
| MIRM * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: MIRM *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine MIRM *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 311 | Chris Peetz | www.mirumpharma.com |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
Mirum Pharmaceuticals, Inc. Fundamentals Summary
| MIRM * fundamental statistics | |
|---|---|
| Market cap | Mex$40.68b |
| Earnings (TTM) | -Mex$2.01b |
| Revenue (TTM) | Mex$6.18b |
6.6x
P/S Ratio-20.2x
P/E RatioIs MIRM * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIRM * income statement (TTM) | |
|---|---|
| Revenue | US$307.03m |
| Cost of Revenue | US$83.88m |
| Gross Profit | US$223.15m |
| Other Expenses | US$322.96m |
| Earnings | -US$99.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 72.68% |
| Net Profit Margin | -32.51% |
| Debt/Equity Ratio | 132.6% |
How did MIRM * perform over the long term?
See historical performance and comparison